ISSUE 1555
| The full article is available to subscribers | Subscriber Login |
The FDA has approved an extended-release tablet formulation of amantadine (Osmolex ER – Vertical/Osmotica) for once-daily treatment of Parkinson's disease (PD) and drug-induced extrapyramidal symptoms (EPS) in adults. An extended-release capsule formulation of amantadine (Gocovri) was approved in 2017 for treatment of levodopa-induced dyskinesia in patients with PD.1
STANDARD TREATMENT — Parkinson's Disease – The combination of levodopa and carbidopa is the most effective treatment for the motor symptoms of PD, but its long-term use leads to motor fluctuations and dyskinesia. Dopamine agonists such as pramipexole (Mirapex, and generics) and ropinirole (Requip, and generics) are less effective than levodopa; they can be used as monotherapy before the introduction of levodopa or as an adjunct to levodopa in patients with motor
... more- Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease. Med Lett Drugs Ther 2017; 59:198.
- Drugs for Parkinson's disease. Med Lett Drugs Ther 2017; 59:187.
- Drugs for psychotic disorders. Med Lett Drugs Ther 2016; 58:160.
- ME Tonda and SK Guthrie. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy 1994; 14:543.
- KM Ward and L Citrome. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia – key differences in pathophysiology and clinical management. Neurol Ther 2018 July 19 (epub).
- RL Woosley and KA Romero. QT drugs list. Available at: www.crediblemeds.org. Accessed August 30, 2018.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1555c
Electronic, downloadable article - $45
